GlassScriptPhysician profile
Mohammed Al-Jasim
NPI 1760479786
$4,958.85
in general payments reported to CMS, 2019-2025
23 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $198 · 2021: $406 · 2022: $676 · 2023: $945 · 2024: $939 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565 · Education: $11.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,564.86 |
| Education | $11.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,333.35 | 2019-2025 | Sunlenca, Biktarvy, Veklury |
| Viiv Healthcare Company | $1,022.90 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Janssen Biotech, INC. | $516.21 | 2019-2023 | Symtuza |
| Janssen Products, LP | $452.59 | 2019-2022 | |
| Smith+Nephew, INC. | $379.36 | 2019-2025 | Collagenase Santyl, Regranex |
| Kci USA, INC. | $234.64 | 2019 | |
| Abbvie INC. | $228.01 | 2021-2025 | Dalvance, Avycaz |
| Insmed, INC. | $142.54 | 2021-2024 | Arikayce |
| Allergan, INC. | $139.31 | 2019 | |
| Boston Scientific Corporation | $92.59 | 2019 | |
| Integra Lifesciences Corporation | $54.63 | 2022 | |
| Paratek Pharmaceuticals, INC. | $51.95 | 2020-2023 | Nuzyra |
| Organogenesis INC. | $50.54 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $44.78 | 2024 | Andexxa |
| Solventum Corporation | $34.89 | 2025 | Activ.A.C., Promogran Prisma, Kerramax Care |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $33.00 | 2019 | |
| Shionogi INC | $27.16 | 2024 | Fetroja |
| Glaxosmithkline, LLC. | $26.39 | 2020 | |
| Abbott Laboratories | $24.61 | 2024 | |
| Biotissue Holdings INC. | $22.34 | 2023 | |
| Aimmune Therapeutics, INC. | $18.33 | 2023 | |
| Emd Serono, INC. | $16.69 | 2025 | |
| Xeris Pharmaceuticals, INC. | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Al-Jasim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.